{"artifact":{"id":"rsc-h-9d07f0457a-e8e64d5a","artifact_type":"rigor_score_card","entity_ids":null,"title":"Rigor Score Card: IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability","quality_score":0.225,"created_by":"rigor_score_card","provenance_chain":"[{\"artifact_id\": \"h-9d07f0457a\", \"relation\": \"scores\"}]","content_hash":null,"metadata":{"dimensions":["scientific_premise","study_design","blinding","power_analysis","resource_identification","statistical_reporting","data_availability","sabv"],"eval_a_raw":{"scores":{"sabv":{"score":1,"evidence":"No mention of sex as a biological variable or disaggregation by sex","location":"Entire document"},"blinding":{"score":1,"evidence":"No mention of assessors, analysts, or blinding procedures","location":"Entire document"},"study_design":{"score":1,"evidence":"The proposed approach: 1. Identify the minimal bioactive sequence: Through alanine scanning and truncation analysis","location":"Design Strategy section"},"power_analysis":{"score":1,"evidence":"No statistical power justification, sample size calculations, or power analysis mentioned","location":"Entire document"},"data_availability":{"score":1,"evidence":"No data, code, or public availability statements present in document","location":"Entire document"},"scientific_premise":{"score":2,"evidence":"Studies of the related IGFBP family have shown that","location":"The Bioactive Domain section"},"statistical_reporting":{"score":1,"evidence":"retain ≥50% of the full-length protein's receptor-binding and signaling activity","location":"Design Strategy section"},"resource_identification":{"score":1,"evidence":"Test the optimized peptide in an in situ brain perfusion model or by measuring brain:plasma ratio","location":"Design Strategy section"}},"overall_summary":"This document is a research proposal/hypothesis framework, not a completed scientific study. It lacks any actual experimental data, statistical analysis, study design, or methodological detail required for biomedical rigor evaluation. All eight dimensions score at minimal levels (1) because the text describes intended future research rather than reporting completed investigations with transparent methodology.","weakest_dimension":"study_design","strongest_dimension":"scientific_premise"},"eval_b_raw":{"scores":{"sabv":{"score":1,"evidence":"In EAE (multiple sclerosis model), IGFBPL1 treatment reduces CNS inflammation and promotes remyelination. No mention of sex disaggregation.","location":"IGFBPL1 Biology and Function section"},"blinding":{"score":1,"evidence":"No mention of blinding procedures in the document","location":"Not applicable"},"study_design":{"score":1,"evidence":"The proposed approach: 1. Identify the minimal bioactive sequence: Through alanine scanning and truncation analysis","location":"Design Strategy for IGFBPL1 Peptide Mimetics section"},"power_analysis":{"score":1,"evidence":"No mention of sample size justification or power calculations","location":"Not applicable"},"data_availability":{"score":1,"evidence":"No data is presented as this is a hypothesis document. Validate CNS penetration: Test the optimized peptide in an in situ brain perfusion model","location":"Design Strategy section"},"scientific_premise":{"score":2,"evidence":"Studies of the related IGFBP family have shown that: 1. The N-terminal region (residues ~30-100) contains the IGF-binding domain","location":"The Bioactive Domain of IGFBPL1 section"},"statistical_reporting":{"score":1,"evidence":"No statistical methods, tests, or thresholds described in the document","location":"Not applicable"},"resource_identification":{"score":1,"evidence":"recombinant N-terminal fragments (1-100 aa) retain partial bioactivity - A synthetic peptide corresponding to residues 45-80","location":"The Bioactive Domain of IGFBPL1 section"}},"overall_summary":"This is a hypothesis/proposal document, not a completed study. The scientific rationale is plausible but relies on vague citations to prior work without specific references. Major deficiencies exist across all methodological dimensions: no study design, no blinding, no power analysis, no RRIDs, no statistical reporting, no data (by design), and no SABV consideration. A hypothesis document cannot be evaluated the same way as a completed study, and this scores poorly on all 8 dimensions when assessed against standard biomedical rigor criteria.","weakest_dimension":"study_design","strongest_dimension":"scientific_premise"},"provider_a":"minimax","provider_b":"minimax-alt","reconciled":{"reconciler_notes":"Both evaluators reached identical scores across all 8 dimensions, yielding perfect agreement. No discrepancies required reconciliation. The document is a research proposal/hypothesis framework, not a completed study, which explains the uniformly low methodological rigor scores (1) across 7 of 8 dimensions. The scientific_premise dimension received a slightly higher score (2) due to references to the related IGFBP family literature. Cohen's kappa calculation is not applicable given the degenerate marginal distributions (all scores identical within each evaluator) and small sample size (8 items).","overall_agreement":"high","reconciled_scores":{"sabv":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of sex as a biological variable or disaggregation by sex","b_evidence":"In EAE (multiple sclerosis model), IGFBPL1 treatment reduces CNS inflammation and promotes remyelination. No mention of sex disaggregation.","disagreement":false},"blinding":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No mention of assessors, analysts, or blinding procedures","b_evidence":"No mention of blinding procedures in the document","disagreement":false},"study_design":{"score":1,"a_score":1,"b_score":1,"a_evidence":"The proposed approach: 1. Identify the minimal bioactive sequence: Through alanine scanning and truncation analysis","b_evidence":"The proposed approach: 1. Identify the minimal bioactive sequence: Through alanine scanning and truncation analysis","disagreement":false},"power_analysis":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No statistical power justification, sample size calculations, or power analysis mentioned","b_evidence":"No mention of sample size justification or power calculations","disagreement":false},"data_availability":{"score":1,"a_score":1,"b_score":1,"a_evidence":"No data, code, or public availability statements present in document","b_evidence":"No data is presented as this is a hypothesis document. Validate CNS penetration: Test the optimized peptide in an in situ brain perfusion model","disagreement":false},"scientific_premise":{"score":2,"a_score":2,"b_score":2,"a_evidence":"Studies of the related IGFBP family have shown that","b_evidence":"Studies of the related IGFBP family have shown that: 1. The N-terminal region (residues ~30-100) contains the IGF-binding domain","disagreement":false},"statistical_reporting":{"score":1,"a_score":1,"b_score":1,"a_evidence":"retain ≥50% of the full-length protein's receptor-binding and signaling activity","b_evidence":"No statistical methods, tests, or thresholds described in the document","disagreement":false},"resource_identification":{"score":1,"a_score":1,"b_score":1,"a_evidence":"Test the optimized peptide in an in situ brain perfusion model or by measuring brain:plasma ratio","b_evidence":"recombinant N-terminal fragments (1-100 aa) retain partial bioactivity - A synthetic peptide corresponding to residues 45-80","disagreement":false}},"inter_rater_agreement":"N/A","dimensions_with_disagreement":[]},"_schema_version":1,"scored_entity_id":"h-9d07f0457a","scored_entity_type":"hypothesis","scored_entity_title":"IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability"},"created_at":"2026-04-26T22:42:22.648534-07:00","updated_at":"2026-04-26T22:42:22.648538-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-26T22:42:22.648534-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"c5ec0e2d-a265-4729-aade-8899cfed1a9d","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"rigor_score_card"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"rsc-h-9d07f0457a-e8e64d5a","is_canonical":true,"supersede_chain":["rsc-h-9d07f0457a-e8e64d5a"]}